Table 1.
Participant Characteristics
| Statin Use at Diagnosis | Daily NSAID Use at Diagnosis | |||||
|---|---|---|---|---|---|---|
| Yes (n=136) |
No (N=550) |
P value | Yes (n=230) |
No (N=456) |
P value | |
| Age at diagnosis (median, years) | 69 | 66 | 0.01 | 69 | 65 | <0.0001 |
| Male | 92 (68%) | 322 (59%) | 0.05 | 156 (68%) | 258 (57%) | 0.005 |
| CD38 |
0.32 |
0.46 |
||||
| Positive | 29 (24%) | 82 (20%) | 42 (22%) | 69 (20%) | ||
| Negative | 93 (76%) | 335 (80%) | 146 (78%) | 282 (80%) | ||
| Missing | 14 | 133 | 42 | 105 | ||
| ZAP-70 |
0.02 |
0.94 |
||||
| Positive | 11 (14%) | 73 (27%) | 30 (24%) | 54 (25%) | ||
| Negative | 66 (86%) | 194 (73%) | 94 (76%) | 166 (75%) | ||
| Missing | 59 | 283 | 106 | 236 | ||
| IGHV |
0.004 |
0.61 |
||||
| Unmutated | 10 (15%) | 80 (33%) | 28 (27%) | 62 (30%) | ||
| Mutated | 57 (85%) | 163 (67%) | 75 (73%) | 145 (70%) | ||
| Missing | 69 | 307 | 127 | 249 | ||
| FISH |
0.20 |
0.64 |
||||
| 13q- | 27 (39%) | 96 (49%) | 39 (42%) | 84 (49%) | ||
| Normal | 22 (32%) | 60 (30%) | 31 (33%) | 51 (30%) | ||
| Trisomy 12 | 15 (22%) | 22 (11%) | 15 (16%) | 22 (13%) | ||
| 11q- | 1 (1%) | 10 (5%) | 3 (3%) | 8 (5%) | ||
| 17p- | 3 (4%) | 6 (3%) | 5 (5%) | 4 (2%) | ||
| Other | 1 (1%) | 3 (2%) | 1 (1%) | 3 (2%) | ||
| Missing | 67 | 353 | 136 | 284 | ||
| Time to First Treatment (median, years) | 7.9 | 11.8 | 0.52 | Not reached |
11.8 | 0.88 |
| Type of First Treatment | ||||||
| Purine analogue monotherapy | 1 (4%) | 6 (6%) | 0.43 | 1 (3%) | 6 (8%) | 0.81 |
| Rituximab containing purine analogue combination | 11 (44%) | 29 (31%) | 15 (38%) | 25 (32%) | ||
| Alkylating agent monotherapy (+/- steroid) | 4 (16%) | 31 (33%) | 12 (31%) | 23 (29%) | ||
| Rituximab containing alkylating agent combination | 3 (12%) | 5 (5%) | 3 (8%) | 5 (6%) | ||
| Antibody therapy with chemo | 5 (20%) | 16 (17%) | 7 (18%) | 14 (18%) | ||
| Other | 1 (4%) | 6 (6%) | 1 (3%) | 6 (8%) | ||
| Survival (median, years) | 10.1 | 11.4 | 0.10 | 10.6 | 11.9 | 0.02 |